RetinalGeniX Technologies Inc. announced that it has contracted with Avania CRO to provide guidance for the Company?s interactions with the FDA for the development of RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD) and RTG-2024 for the treatment of Alzheimer?s syndrome dementia, and the RetinalCam? image visualization device. Overall, RetinalGeniX now has advisors for each of its three components of precision ophthalmology.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.5 USD | +12.90% | -.--% | +13.27% |
1st Jan change | Capi. | |
---|---|---|
+13.27% | 62.25M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- RTGN Stock
- News RetinalGenix Technologies Inc.
- RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam? Image Visualization Device